Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Analysts

Cencora, Inc. (NYSE:COR) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $233.90.

Several analysts have recently issued reports on the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Cencora in a report on Monday, February 26th. Citigroup boosted their target price on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird boosted their target price on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Finally, SVB Leerink assumed coverage on Cencora in a research report on Monday, February 26th. They set an “outperform” rating and a $261.00 target price on the stock.

Cencora Stock Down 1.2 %

Shares of COR opened at $224.04 on Thursday. The stock has a market capitalization of $44.69 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 1.61 and a beta of 0.47. Cencora has a 1 year low of $163.37 and a 1 year high of $246.75. The business’s 50 day simple moving average is $237.58 and its 200-day simple moving average is $219.90. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.65 by $0.15. The business had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.50 EPS. As a group, equities analysts expect that Cencora will post 13.44 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 24th. Shareholders of record on Friday, May 10th will be given a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Steven H. Collis sold 10,754 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the transaction, the chief executive officer now owns 285,088 shares of the company’s stock, valued at approximately $67,702,698.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Cencora news, EVP Gina Clark sold 1,100 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $230.48, for a total value of $253,528.00. Following the completion of the sale, the executive vice president now directly owns 24,802 shares in the company, valued at approximately $5,716,364.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Steven H. Collis sold 10,754 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The disclosure for this sale can be found here. Insiders have sold 76,395 shares of company stock valued at $18,001,472 in the last quarter. 15.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Cencora

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. purchased a new stake in shares of Cencora during the 4th quarter worth $4,212,508,000. Bank of New York Mellon Corp purchased a new stake in shares of Cencora during the 1st quarter worth $291,825,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Cencora during the 1st quarter worth $238,457,000. Mawer Investment Management Ltd. purchased a new stake in shares of Cencora during the 1st quarter worth $191,309,000. Finally, Swiss National Bank purchased a new stake in shares of Cencora during the 1st quarter worth $124,144,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.